切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2011, Vol. 05 ›› Issue (02) : 209 -214. doi: 10.3877/cma.j.issn.1674-0807.2011.02.013

综述

乳腺癌相关DNA 甲基化生物标记的研究进展
苏怡1, 任泽舫1,()   
  1. 1.510080 广州,中山大学公共卫生学院医学统计与流行病学系
  • 收稿日期:2010-05-10 出版日期:2011-04-01
  • 通信作者: 任泽舫
  • 基金资助:
    国家自然科学基金项目(81072383)

DNA methylation in breast cancer

Yi SU, Ze-fang REN()   

  • Received:2010-05-10 Published:2011-04-01
  • Corresponding author: Ze-fang REN
引用本文:

苏怡, 任泽舫. 乳腺癌相关DNA 甲基化生物标记的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2011, 05(02): 209-214.

Yi SU, Ze-fang REN. DNA methylation in breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2011, 05(02): 209-214.

[1]
Parkin DM,Bray F,Ferlay J,et al. Global cancer statistics,2002[J]. CA Cancer J Clin,2005,55(2):74-108.
[2]
Veeck J,Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs[J]. J Mammary Gland Biol Neoplasia,2010,15(1):5-17.
[3]
Korkola J,Gray JW. Breast cancer genomes--form and function[J]. Curr Opin Genet Dev,2010,20(1):4-14.
[4]
Jovanovic J,Ronneberg JA,Tost J,et al. The epigenetics of breast cancer[J]. Mol Oncol,2010,4(3):242-254.
[5]
Wolffe AP,Matzke MA. Epigenetics: Regulation through repression[J]. Science,1999,286(5439):481-486.
[6]
Chuang JC,Jones PA. Epigenetics and microRNAs[J]. Pediatric Research,2007,61(5):24-29.
[7]
Hinshelwood RA,Clark SJ. Breast cancer epigenetics: normal human mammary epithelial cells as a model system[J]. J Mol Med,2008,86(12):1315-1328.
[8]
Jones PA,Baylin SB. The epigenomics of cancer[J]. Cell,2007. 128(4):683-692.
[9]
Eden A,Gaudet F,Waghmare A,et al. Chromosomal instability and tumors promoted by DNA hypomethylation[J]. Science,2003,300(5618):455.
[10]
Ehrlich M. DNA hypomethylation,cancer,the immunodeficiency,centromeric region instability,facial anomalies syndrome and chromosomal rearrangements[J]. J Nutr,2002,132(8 Suppl): S2424-S2429.
[11]
Pakneshan P,Szyf M,Farias Eisner R,et al.,Reversal of the hypomethylation status of urokinase (uPA) promoter blocks breast cancer growth and metastasis[J]. J Biol Chem,2004,279(30):31735-3144.
[12]
Fan M,Yan PS,Hartman Frey C,et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant [J]. Cancer Res,2006,66(24):11954-1166.
[13]
Martens JWM,Margossian AL,Schmitt M,et al. DNA methylation as a biomarker in breast cancer[J]. Future Oncol,2009,5(8):1245-1256.
[14]
Lo PK,Sukumar S. Epigenomics and breast cancer. Pharma-cogenomics,2008,9(12):1879-1902.
[15]
Sharma G,Mirza S,Parshad R,et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients[J]. Clin Biochem,2010,43(4/5):373-379.
[16]
Widschwendter M,Apostolidou S,Raum E,et al. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study[J]. PLoS One,2008,3(7):e2656.
[17]
Muller HM,Widschwendter A,Fiegl H,et al. DNA methylation in serum of breast cancer patients: an independent prognostic marker[J]. Cancer Res,2003,63(22):7641-7645.
[18]
Li Y,Wei Q,Cao F,et al. Expression and promoter methylation of the RASSF1A gene in sporadic breast cancers in Chinese women[J]. Oncol Rep,2008,19(5):1149-1153.
[19]
Lewis CM,Cler LR,Bu DW,et al. Promoter hypermethylation in benign breast epithelium in relation to predicted breast cancer risk[J]. Clin Cancer Res,2005,11(1):166-172.
[20]
Kim JH,Shin MH,Kweon SS,et al. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women[J]. Gynecol Oncol,2010,118(2):176-181.
[21]
Ahmed IA,Pusch CM,Hamed T,et al. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA[J]. Cancer Genet Cytogenet,2010,199(2):96-100.
[22]
Van der Auwera I,Bovie C,Svensson C,et al. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients[J]. BMC Cancer,2010,10:97.
[23]
Wilson ME,Westberry JM. Regulation of oestrogen receptor gene expression: new insights and novel mechanisms[J]. J Neuroendocrinol,2009,21(4):238-242.
[24]
Fiegl H,Millinger S,Mueller Holzner E,et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients[J]. Cancer Res,2005,65(4):1141-1145.
[25]
Fiegl H,Jones A,Hauser Kronberger C,et al. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer[J]. Clin Cancer Res,2008,14(11):3494-3502.
[26]
Dietrich D,Krispin M,Dietrich J,et al. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated,estrogen receptor-positive,lymph node-positive breast cancer patients[J]. BMC Cancer,2010,10:247.
[27]
Karray Chouayekh S,Trifa F,Khabir A,et al. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients[J]. J Cancer Res Clin Oncol,2010,136(2):203-210.
[28]
Campan M,Weisenberger DJ,Laird PW. DNA methylation profiles of female steroid hormone-driven human malignancies[J].Curr Top Microbiol Immunol,2006,310:141-178.
[29]
Dworkin AM,Huang THM,Toland AE. Epigenetic alterations in the breast: Implications for breast cancer detection,prognosis and treatment[J]. Semin Cancer Biol,2009,19(3):165-171.
[30]
Sharma G,Mirza S,Parshad R,et al. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients[J]. Life Sci,2010,87(3/4):83-91.
[31]
Jing F,Jun L,Yong Z,et al. Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker[J]. Oncology,2008,75(1/2):60-66.
[32]
Evron E,Dooley WC,Umbricht CB,et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR[J]. Lancet,2001,357(9265):1335-1336.
[33]
Fackler MJ,McVeigh M,Mehrotra J,et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer[J]. Cancer Res,2004,64(13):4442-4452.
[34]
Fackler MJ,Malone K,Zhang Z,et al. Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid[J]. Clin Cancer Res,2006,12(11 Pt 1):3306-3310.
[35]
Jing F,Yuping W,Yong C,et al. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma[J].Tumour Biol,2010,31(4):321-331.
[36]
Brooks J,Cairns P,Zeleniuch Jacquotte A. Promoter methylation and the detection of breast cancer[J]. Cancer Causes Control,2009,20(9):1539-1550.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[3] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[4] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[5] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[6] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[7] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[8] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[9] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[12] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?